特应性皮炎患者蛋白质组、miRNA及细菌生物标志物模式及其抗IL-4Rα治疗后的变化
该研究在特应性皮炎(AD)患者中开展蛋白质组和miRNA筛查并与健康对照比较,随后在50例AD患者中于系统度普利尤单抗治疗前后连续检测差异调节的血清蛋白、miRNA及选定皮肤微生物群,并用随机森林分类器基于初始生物标志物模式预测治疗结局。研究发现27个蛋白质组候选标志物、miRNA及三种微生物菌株在AD中失调,其中CCL17、CCL13、CCL22、E-selectin和BDNF与治疗应答显著相关,而微生物组成和miRNA模式均与度普利尤单抗治疗应答无关。
要点
- CCL17、CCL13、CCL22、E-selectin和BDNF与度普利尤单抗治疗应答显著相关。
- 微生物组成和miRNA模式均与度普利尤单抗治疗应答无关。
- 抗IL-4Rα治疗后蛋白质组谱和选定皮肤细菌发生深刻变化并与总体临床应答相关。
核心结论
- AD患者存在明确的系统性蛋白质组血清谱、miRNA模式和皮肤微生物组失调。
- 蛋白质组谱和选定皮肤细菌在抗IL-4Rα治疗后发生深刻变化,且与总体临床应答相关,而miRNA相关生物标志物未见此关联。
- 研究结果支持生物标志物谱反映治疗应答的假说,未来或可用于开发AD个体化医疗方法。
研究设计与样本
- 在AD患者与健康对照中开展蛋白质组和miRNA筛查。
- 在50例AD患者中于系统度普利尤单抗治疗前及治疗后连续检测差异调节的血清蛋白、miRNA和选定皮肤微生物群。
- 使用随机森林分类器基于初始生物标志物模式预测度普利尤单抗治疗结局。
主要发现
- 鉴定出27个蛋白质组候选标志物、miRNA及三种微生物菌株在AD中失调。
- CCL17、CCL13、CCL22、E-selectin和BDNF表达差异调节且与治疗应答显著相关。
- 微生物组成和miRNA模式均与度普利尤单抗治疗应答无关。
临床怎么用
- CCL17、CCL13、CCL22、E-selectin和BDNF等血清蛋白标志物有望辅助预测AD患者对度普利尤单抗的治疗应答。
- 皮肤微生物组成和miRNA模式暂不宜作为度普利尤单抗治疗应答的预测指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Identification of biomarkers is required for a systems medicine approach and personalized treatment in atopic dermatitis (AD). These biomarkers may not only aid in diagnosing but also might be suitable to predict the effectiveness of targeted treatment. OBJECTIVE: We aimed to identify proteomic, microbial and miRNA biomarkers in AD patients and investigated their course in relation to the clinical response upon anti-IL-4Rα therapy. METHODS: Proteomic and miRNA screening was performed in AD patients in comparison to healthy controls. Differentially regulated serum proteins, miRNA and selected skin microbiota were measured consecutively in 50 AD patients before and upon systemic dupilumab treatment. A random forest classifier was used to predict the outcome of dupilumab therapy based on the initial biomarker patterns. RESULTS: We identified 27 proteomic candidates, miRNA and three microbial strains to be dysregulated in AD. CCL17, CCL13, CCL22, E-selectin and BDNF were differently regulated and significantly associated with treatment response. In contrast, neither the microbial composition nor the miRNA pattern was associated with treatment response upon dupilumab treatment. CONCLUSION: AD patients display defined dysregulations regarding their systemic proteomic serum profile, miRNA patterns and their skin microbiome. The proteomic profile and selected skin bacteria changed profoundly upon anti-IL-4Rα therapy which was associated with an overall clinical response. This was not seen in miRNA-related biomarkers. Our findings support the hypothesis that biomarker profiles reflect treatment responses and may in the future be used to develop a personalized medicine approach for the treatment of AD patients.
引用
- Pažur K, Francuzik W, El-Mahmoud H, et al. Proteomic, miRNA and bacterial biomarker patterns in atopic dermatitis patients and their course upon anti-IL-4Rα therapy. J Eur Acad Dermatol Venereol. 2024. PMID: 38379385. doi:10.1111/jdv.19911
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。